Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis

Teppei Yamaguchi, Hideki Hayashi, Sumito Isogai, Masamichi Hayashi, Sakurako Uozu, Yasuhiro Goto, Toru Nakanishi, Tadashi Sugiyama, Yoshinori Itoh, Kazuyoshi Imaizumi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Recent analysis indicated that afatinib could be effective in treating non-small cell lung cancer harboring uncommon EGFR mutations. A 59-year-old man undergoing hemodialysis for chronic renal failure was diagnosed with adenocarcinoma of the lung (cT4N3M1b). EGFR mutation analysis of his cancer revealed G719A point mutation in exon 18, and we started daily administration of 30. mg afatinib with hemodialysis (three times a week). As the feasibility of afatinib in patients with chronic renal failure undergoing hemodialysis has not been established, we analyzed the pharmacokinetics of afatinib in this patient. The trough level of afatinib in his plasma was almost similar to that of patients with normal renal function. Two months later there was marked tumor shrinkage, indicating a partial response. Our results suggest that afatinib could be safely administered and may exhibit good tumor response in a patient who has advanced lung adenocarcinoma with uncommon mutations undergoing hemodialysis.

Original languageEnglish
Pages (from-to)169-171
Number of pages3
JournalCancer Treatment Communications
Volume4
DOIs
Publication statusPublished - 01-01-2015

Fingerprint

Non-Small Cell Lung Carcinoma
Renal Dialysis
Mutation
Chronic Kidney Failure
Neoplasms
Point Mutation
BIBW 2992
Exons
Pharmacokinetics
Kidney
Adenocarcinoma of lung

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Yamaguchi, Teppei ; Hayashi, Hideki ; Isogai, Sumito ; Hayashi, Masamichi ; Uozu, Sakurako ; Goto, Yasuhiro ; Nakanishi, Toru ; Sugiyama, Tadashi ; Itoh, Yoshinori ; Imaizumi, Kazuyoshi. / Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis. In: Cancer Treatment Communications. 2015 ; Vol. 4. pp. 169-171.
@article{56dff3bb549e43db9baf894b44304706,
title = "Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis",
abstract = "Recent analysis indicated that afatinib could be effective in treating non-small cell lung cancer harboring uncommon EGFR mutations. A 59-year-old man undergoing hemodialysis for chronic renal failure was diagnosed with adenocarcinoma of the lung (cT4N3M1b). EGFR mutation analysis of his cancer revealed G719A point mutation in exon 18, and we started daily administration of 30. mg afatinib with hemodialysis (three times a week). As the feasibility of afatinib in patients with chronic renal failure undergoing hemodialysis has not been established, we analyzed the pharmacokinetics of afatinib in this patient. The trough level of afatinib in his plasma was almost similar to that of patients with normal renal function. Two months later there was marked tumor shrinkage, indicating a partial response. Our results suggest that afatinib could be safely administered and may exhibit good tumor response in a patient who has advanced lung adenocarcinoma with uncommon mutations undergoing hemodialysis.",
author = "Teppei Yamaguchi and Hideki Hayashi and Sumito Isogai and Masamichi Hayashi and Sakurako Uozu and Yasuhiro Goto and Toru Nakanishi and Tadashi Sugiyama and Yoshinori Itoh and Kazuyoshi Imaizumi",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.ctrc.2015.09.006",
language = "English",
volume = "4",
pages = "169--171",
journal = "Cancer Treatment and Research Communications",
issn = "2213-0896",
publisher = "Elsevier Ltd",

}

Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis. / Yamaguchi, Teppei; Hayashi, Hideki; Isogai, Sumito; Hayashi, Masamichi; Uozu, Sakurako; Goto, Yasuhiro; Nakanishi, Toru; Sugiyama, Tadashi; Itoh, Yoshinori; Imaizumi, Kazuyoshi.

In: Cancer Treatment Communications, Vol. 4, 01.01.2015, p. 169-171.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis

AU - Yamaguchi, Teppei

AU - Hayashi, Hideki

AU - Isogai, Sumito

AU - Hayashi, Masamichi

AU - Uozu, Sakurako

AU - Goto, Yasuhiro

AU - Nakanishi, Toru

AU - Sugiyama, Tadashi

AU - Itoh, Yoshinori

AU - Imaizumi, Kazuyoshi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Recent analysis indicated that afatinib could be effective in treating non-small cell lung cancer harboring uncommon EGFR mutations. A 59-year-old man undergoing hemodialysis for chronic renal failure was diagnosed with adenocarcinoma of the lung (cT4N3M1b). EGFR mutation analysis of his cancer revealed G719A point mutation in exon 18, and we started daily administration of 30. mg afatinib with hemodialysis (three times a week). As the feasibility of afatinib in patients with chronic renal failure undergoing hemodialysis has not been established, we analyzed the pharmacokinetics of afatinib in this patient. The trough level of afatinib in his plasma was almost similar to that of patients with normal renal function. Two months later there was marked tumor shrinkage, indicating a partial response. Our results suggest that afatinib could be safely administered and may exhibit good tumor response in a patient who has advanced lung adenocarcinoma with uncommon mutations undergoing hemodialysis.

AB - Recent analysis indicated that afatinib could be effective in treating non-small cell lung cancer harboring uncommon EGFR mutations. A 59-year-old man undergoing hemodialysis for chronic renal failure was diagnosed with adenocarcinoma of the lung (cT4N3M1b). EGFR mutation analysis of his cancer revealed G719A point mutation in exon 18, and we started daily administration of 30. mg afatinib with hemodialysis (three times a week). As the feasibility of afatinib in patients with chronic renal failure undergoing hemodialysis has not been established, we analyzed the pharmacokinetics of afatinib in this patient. The trough level of afatinib in his plasma was almost similar to that of patients with normal renal function. Two months later there was marked tumor shrinkage, indicating a partial response. Our results suggest that afatinib could be safely administered and may exhibit good tumor response in a patient who has advanced lung adenocarcinoma with uncommon mutations undergoing hemodialysis.

UR - http://www.scopus.com/inward/record.url?scp=84947944691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947944691&partnerID=8YFLogxK

U2 - 10.1016/j.ctrc.2015.09.006

DO - 10.1016/j.ctrc.2015.09.006

M3 - Article

VL - 4

SP - 169

EP - 171

JO - Cancer Treatment and Research Communications

JF - Cancer Treatment and Research Communications

SN - 2213-0896

ER -